Navigation Links
Pixantrone Combination Therapy for First-line Treatment of,Aggressive Non-Hodgkin's Lymphoma Results in Reduction in Severe,Toxicities Including Heart Damage When Compared to,Doxorubicin-based Therapy

Positive interim results prompt request for meeting with FDA

SEATTLE, July 11, 2007 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) announced today that interim results of its phase II/III trial comparing CPOP-R, in which pixantrone is substituted for doxorubicin in standard CHOP-R first-line treatment of patients with aggressive non-Hodgkin's lymphoma (NHL), resulted in essentially all patients on both arms achieving a major objective anti-tumor response (complete response or partial response). The preliminary results showed that patients who received pixantrone had a reduction in severe (grade 3/4) side effects when compared to patients treated with standard doxorubicin-based therapy. The Company intends to report data from this trial, known as RAPID, at the American Society of Hematology (ASH) annual meeting in December.

Despite pixantrone patients receiving more treatment cycles, a three-fold reduction in the incidence of severe heart damage (LVEF decline >15 percent) was seen as well as clinically significant reductions in infections and thrombocytopenia. In addition a significant reduction in febrile neutropenia was also observed. Febrile neutropenia is a life-threatening complication of chemotherapy which often requires hospitalization and antibiotic therapy and may lead to death from infection while the patient's infection-fighting white blood cells are low due to neutropenia. The RAPID study is expected to complete enrollment in 2008.

"We are excited by these results demonstrating that pixantrone is living up to the promise of preventing the severe cardiac damage that accompanies the use of standard doxorubicin treatment while retaining the potent anti-lymphoma activity of this class of drug," said James A. Bianco, M.D., President and CEO of CTI. "Pending results from this and other studies, these findings could have major implications for treating patients with breast cancer, lym
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
3. Pixantrone Granted Fast Track Designation by FDA for Relapsed Indolent NHL Patients
4. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
5. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
6. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
7. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
8. Poniard Pharmaceuticals Announces Promising Data From Interim Safety Analysis of Phase 1 Combination Trials of Picoplatin in Colorectal and Prostate Cancers
9. Peregrine Pharmaceuticals Reports Positive Top-Line Results in Bavituximab Combination Therapy Trial in Advanced Cancer Patients
10. Intarcia Therapeutics Announces Presentation of Final Results From a Phase 2 Combination Study for the Treatment of Hepatitis C at the Digestive Disease Week Conference
11. Data Presented at ASH Demonstrate Nebivolol Lowers Blood Pressure as Long-Term Monotherapy and in Combination Therapy

Post Your Comments:
(Date:11/19/2009)...reland, Nov. 19 Warner Chilcott pl...its previously announced secondary offering of 20,...ublic of $22.25 per share. The selling shareholde...ners, DLJ Merchant Banking, J.P. Morgan Partners (...s, L.P., certain other institutional investors and...
(Date:11/19/2009)...VIEW, Calif., Nov. 19 Al...ced today that its corporate presentation will be ...Health Care Conference on Wednesday, December 2, 2...ill be webcast from The New York Palace Hotel in N...lexza President and CEO. ,, To access the liv...
(Date:11/19/2009)...of International Internet Week of Action ,, SI...-- The U.S. Food and Drug Administration today com...rt, called the International Internet Week of Acti...ing medical products. ,, (Logo: http://www.new...ing the effort, the FDA,s Office of Criminal Inves...
Breaking Medicine Technology:Warner Chilcott Prices Secondary Equity Offering 2Warner Chilcott Prices Secondary Equity Offering 3Warner Chilcott Prices Secondary Equity Offering 4Alexza Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference 2Alexza Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference 3UPDATE: FDA Issues 22 Warning Letters to Web site Operators 2Lilly Receives Fourth FDA Approval for ALIMTA 28R 29 28pemetrexed for injection 29 50746 1Lilly Receives Fourth FDA Approval for ALIMTA 28R 29 28pemetrexed for injection 29 50746 2Lilly Receives Fourth FDA Approval for ALIMTA 28R 29 28pemetrexed for injection 29 50746 3Lilly Receives Fourth FDA Approval for ALIMTA 28R 29 28pemetrexed for injection 29 50746 4Lilly Receives Fourth FDA Approval for ALIMTA 28R 29 28pemetrexed for injection 29 50746 5Lilly Receives Fourth FDA Approval for ALIMTA 28R 29 28pemetrexed for injection 29 50746 6Lilly Receives Fourth FDA Approval for ALIMTA 28R 29 28pemetrexed for injection 29 50746 7Fish Fuels Young Mens Brains 50744 1Fish Fuels Young Mens Brains 50744 2Fish Fuels Young Mens Brains 50744 3New Moms Urged to Take Care of Postpartum Health 50742 1New Moms Urged to Take Care of Postpartum Health 50742 2
...se-Response Trends Suggest Improved Efficacy with ... - Dose Escalation Ongoing -, ... (Nasdaq: MDVN ) today announced that data from a...s novel androgen receptor antagonist,MDV3100, show...declining,serum levels of prostate specific antige...
... 2 Physicians affiliated with the US,Oncology Res...clinical,research at the 44th Annual Meeting of th...d May 30 - June 3, 2008 in Chicago., Dr. Joyce O,...mons,Cancer Center, an affiliate of US Oncology, g...ized Phase III trial that studied lapatanib (L) al...
Other Medicine Technology:Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients at 44th ASCO Annual Meeting 2Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients at 44th ASCO Annual Meeting 3Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients at 44th ASCO Annual Meeting 4US Oncology Affiliated Physicians Make a Strong Showing in ASCO Proceedings 2US Oncology Affiliated Physicians Make a Strong Showing in ASCO Proceedings 3US Oncology Affiliated Physicians Make a Strong Showing in ASCO Proceedings 4US Oncology Affiliated Physicians Make a Strong Showing in ASCO Proceedings 5
(Date:11/20/2009)...gs in children with chronic kidney disease often f...ffice visits increasing a child,s risk for seriou... Hopkins Children,s Center and other institutions....urnal of American Society of Nephrology. , Res...ined during regular doctor visits to readings obta...
(Date:11/20/2009)...as 34 weeks, potentially adding to preemie deliver...(HealthDay News) -- Recent reports show that the r...e United States. Now, a new study suggests one re...itutes a full-term birth in the first place. , ...tudy considered a baby born at 34 to 36 weeks of g...
(Date:11/20/2009)...gh and is expected to continue, CDC says, , ...eas of the United States are seeing declines in H1...aid Friday, and while the disease remains widespre...ported last week. , "We are beginning to see so...ry, but there is still a lot of influenza everywhe...
(Date:11/20/2009)... Nov. 20 Missouri state employees ...s will now have the option to choose Mercy Health ...en Missouri Consolidated Health Care Plan (MCHCP) ...uth Central Missouri regions include the following...Dallas, Douglas, Greene, Hickory, Howell, Jasper, ...
(Date:11/20/2009)... Nov. 20 The Louisi...d that Louisianians could experience higher health...eing considered by Congress should become law. ,... for LAHP, "Louisiana health plans have supported ...ng of the national debate. Our plans have offered...
Breaking Medicine News(10 mins):Health News:High blood pressure easy to miss in children with kidney disease 2Health News:Many Women Miscalculate Time to Full-Term Birth 2Health News:Many Women Miscalculate Time to Full-Term Birth 3Health News:Many Women Miscalculate Time to Full-Term Birth 4Health News:Swine Flu Declining in Some Parts of U.S. 2Health News:Swine Flu Declining in Some Parts of U.S. 3Health News:Missouri Consolidated Health Care Plan Provides Mercy Health Plans Option 2Health News:Congressional Health Care Reform Proposals Would Make Health Care More Expensive, Reduce Benefits for Louisianians 2
...sically active may be getting benefits beyond sala...ed risk of developing prostate cancer, according t...archers studied more than 2,100 men who worked at ...n cancers. The research team identified 362 men wh...
...edictive medicine company,PreMD Inc. (TSX: PMD; Am...,business direction in light of the recent decisio...., Appeal to the FDA, PreMD today filed a reques...on Jan. 15, the company received a,non-substantial...
...ship Experience to CTG,s Board, BUFFALO, N.Y., Fe...rmation technology (IT) staffing and solutions com...lected William D. McGuire, a,healthcare executive ...om 2002 to 2005 as President and CEO of Kaleida,He...
...sdaq: TSTF ) a national provider of healthcare an...y that it is changing the name of its,government s...eamStaff,Government Solutions (dba TeamStaff GS).,...le contracts with both the United States General S...
...,Inc. (OTC Bulletin Board: IGTG), a medical device...tion agreement with Progressive International,Hold...in Taiwan, People,s,Republic of China, Japan and K... company, Progressive Group,Inc (PGI), was founded...
...n,(Nasdaq: IOMI ) today announced the interim res...f the two-dose regimen for its novel, patch-based,... response when,self-applied by subjects outside of... which is,approximately the size and shape of an a...
Other Medicine News:Health News:Men who are continually active at work may have a decreased risk of prostate cancer 2Health News:Men who are continually active at work may have a decreased risk of prostate cancer 3Health News:PreMD Initiates FDA Review Process and Provides Corporate Update 2Health News:PreMD Initiates FDA Review Process and Provides Corporate Update 3Health News:CTG Names William D. McGuire a Director 2Health News:CTG Names William D. McGuire a Director 3Health News:TeamStaff Renames Subsidiary to Reflect Expanding Government Services 2Health News:TeamStaff Renames Subsidiary to Reflect Expanding Government Services 3Health News:Ingen Technologies Brings Oxyview(R) to Asia Through Major Medical Distributor 2Health News:Ingen Technologies Brings Oxyview(R) to Asia Through Major Medical Distributor 3Health News:Iomai Study Shows Self-Applied Travelers' Diarrhea Vaccine Patch Comparable to Clinician-Applied Vaccine Patch 2Health News:Iomai Study Shows Self-Applied Travelers' Diarrhea Vaccine Patch Comparable to Clinician-Applied Vaccine Patch 3Health News:Iomai Study Shows Self-Applied Travelers' Diarrhea Vaccine Patch Comparable to Clinician-Applied Vaccine Patch 4
96-Well Plate Sealing Film
...contained work area that will help protect your PC...ate the work area prior to use, reducing the possi...ontainment features reduce the chance of airborne ...c windows for a clear view, an acid-resistant blac...
Remote Alpha Dock system
...gned for low to medium throughput reading of entir...from one to three racks and reads in approximately...orted via text files and a list of ActiveX control...programs. System includes a USB HP Scanner and sof...
Medicine Products: